Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies

PURPOSE: To date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA) across diverse cancers and the role of anti-EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Shumei, Okamura, Ryosuke, Mareboina, Manvita, Lee, Suzanna, Goodman, Aaron, Patel, Sandip P., Fanta, Paul T., Schwab, Richard B., Vu, Peter, Raymond, Victoria M., Lanman, Richard B., Sicklick, Jason K., Lippman, Scott M., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497417/
https://www.ncbi.nlm.nih.gov/pubmed/31058253
http://dx.doi.org/10.1200/PO.18.00180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497417/
https://www.ncbi.nlm.nih.gov/pubmed/31058253
http://dx.doi.org/10.1200/PO.18.00180

Ejemplares similares